



Press release |

New Proton Therapy Order: PROCURE contracts once more with IBA for its new Center in New Jersey

Embargo up until 5.40 p.m. (Belgian time) – February 23rd, 2010

Louvain-la-Neuve, Belgium, February 23rd, 2010 – IBA (Ion Beam Applications S.A.) announced today that it has closed with ProCure Treatment Centers, Inc. the contract to supply a proton therapy system at the ProCure Proton Therapy Center in Somerset, New Jersey, USA. The contract is financed and in full force.

IBA has built its reputation as a leader in technology innovation and operational excellence. Today, despite a challenging economic climate, IBA continues to demonstrate leadership and experience also in developing financing unique solutions together with its banking network. This facilitates the acquisition process for its clients.

The Proton Therapy system will include four treatment rooms - a combination of gantry (isocentric rotating frames), inclined beam and fixed beam rooms - with the latest options for patient positioning and the IBA Universal Nozzle technology, including the latest Pencil Beam Scanning. The relationship will also include a long-term service and maintenance agreement. The center is expected to treat its first patient in 2012.

“We are excited about working with IBA on another proton therapy center”, said Hadley Ford, ProCure's Chief Executive Officer. “IBA is the industry leader in proton therapy technology and we have been able to count on them to develop innovations with a focus on precision, safety and patient comfort”.

Proton Therapy is increasingly considered as the best radiotherapy for cancer due to its superior dose distribution. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, and better spare healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risks of side effects and long term complications, improving outcomes and quality of life for patients. Unfortunately, very few patients can yet benefit from this type of treatment around the world.

IBA is continuing its efforts to make Particle Therapy available worldwide. Concretely, as of today seven proton therapy centers, built by IBA, are treating patients every day in the USA and Asia. Beside them, IBA manages the simultaneous construction and installation of nine additional proton therapy centers, five in USA and four in Europe.



Press release |

ABOUT PROCURE TREATMENT CENTERS, INC.

ProCure Treatment Centers, Inc., based in Bloomington, Ind., was founded in 2005 to improve the lives of patients with cancer by increasing access to proton therapy. ProCure collaborates with leading radiation oncology practices and hospitals and provides management leadership and a comprehensive approach for the design, construction, financing, staffing, training and day-to-day operations of world-class proton therapy centers. ProCure's solution reduces the time, cost and effort necessary to create a facility. ProCure is the only company in the world with a center open and treating patients (Oklahoma City), another under construction in suburban Chicago (Warrenville) to open in early 2011, and four others in development (Seattle; Somerset, N.J.; South Florida; and Detroit). ProCure's Training and Development Center is the first facility in the world dedicated exclusively to proton therapy. For more information, visit www.procure.com.

ABOUT IBA

IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: www.iba-worldwide.com

Contact

IBA

Thomas Ralet
VP Corporate Communication
Tel.: +32 10 47 58 90
InvestorRelations@iba-group.com